Jacobs Levy Equity Management
GBIO

Jacobs Levy Equity Management’s Generation Bio GBIO Stock Holding History

Jacobs Levy Equity Management’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,201
Closed -$73.7K – 1085
2025
Q1 		$73.7K Sell
18,201
-12,953
-42% -$91K ﹤0.01% 1052
2024
Q4 		$330K Buy
31,154
+3,809
+14% +$67.9K ﹤0.01% 860
2024
Q3 		$675K Sell
27,345
-2,760
-9% -$73K ﹤0.01% 794
2024
Q2 		$849K Buy
30,105
+26,870
+831% +$873K ﹤0.01% 772
2024
Q1 		$132K Sell
3,235
-5,619
-63% -$132K ﹤0.01% 908
2023
Q4 		$146K Buy
+8,854
New +$154K ﹤0.01% 942
2023
Q2 		– Sell
-1,527
Closed -$65.7K – 1010
2023
Q1 		$65.7K Sell
1,527
-6,690
-81% -$324K ﹤0.01% 938
2022
Q4 		$323K Sell
8,217
-6,410
-44% -$337K ﹤0.01% 854
2022
Q3 		$777K Buy
14,627
+10,993
+303% +$688K 0.01% 762
2022
Q2 		$238K Buy
+3,634
New +$238K ﹤0.01% 948

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jacobs Levy Equity Management's GBIO Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Generation Bio (GBIO) in Q2 2025, closing a stake of 18,201 shares — an estimated $73.7K sold.

Jacobs Levy Equity Management first reported a position in GBIO in Q2 2022 and held it in 10 quarters. The position peaked at $849K in Q2 2024. 61 funds tracked by Wall St. Rank hold GBIO as of Q2 2025.

  • Jacobs Levy Equity Management reported no remaining Generation Bio position as of Q2 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 18,201 Generation Bio shares in Q2 2025, an estimated $73.7K.
  • Jacobs Levy Equity Management first reported a position in Generation Bio in Q2 2022 and held it in 10 quarters.
  • Jacobs Levy Equity Management's Generation Bio position peaked at $849K in Q2 2024.
  • 61 funds tracked by Wall St. Rank held Generation Bio as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.